Bakul Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.99 M
as on 24-10-2024
- Company Age 27 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.50 Cr
as on 24-10-2024
- Satisfied Charges ₹ 33.08 Cr
as on 24-10-2024
- Revenue -0.80%
(FY 2023)
- Profit 76.13%
(FY 2023)
- Ebitda 89.95%
(FY 2023)
- Net Worth 23.54%
(FY 2023)
- Total Assets -4.28%
(FY 2023)
About Bakul Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M.
The company currently has active open charges totaling ₹13.50 Cr. The company has closed loans amounting to ₹33.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
Madhavi Majmudar and Yogin Majmudar serve as directors at the Company.
- CIN/LLPIN
U24230MH1997PTC111089
- Company No.
111089
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Oct 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bakul Pharma Private Limited offer?
Bakul Pharma Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, Chemical Intermediates, Formic Acid, Potassium Salts, Potassium Chloroplatinate.
Who are the key members and board of directors at Bakul Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhavi Majmudar  | Director | 16-Jan-1998 | Current |
| Yogin Majmudar | Director | 06-Oct-1997 | Current |
Financial Performance of Bakul Pharma.
Bakul Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.8% decrease. The company also saw a substantial improvement in profitability, with a 76.13% increase in profit. The company's net worth Soared by an impressive increase of 23.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bakul Pharma?
In 2023, Bakul Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bakul Aromatics And Chemicals Private LimitedActive 49 years 9 monthsYogin Majmudar is a mutual person
Puspaj Investment Company Private LimitedActive 48 years 2 monthsMadhavi Majmudar and Yogin Majmudar are mutual person
- Gulbas Investment Private LimitedActive 33 years 11 months
Madhavi Majmudar and Yogin Majmudar are mutual person
- Bakul Finechem Research CentreActive 50 years 3 months
Madhavi Majmudar and Yogin Majmudar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 Oct 2021 | ₹5.50 Cr | Open |
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 29 Nov 2019 | ₹1.50 Cr | Open |
Hdfc Bank Limited Creation Date: 12 Sep 2019 | ₹6.50 Cr | Open |
How Many Employees Work at Bakul Pharma?
Bakul Pharma has a workforce of 92 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bakul Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bakul Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
